Ipsen SA, of Paris, reported results of the international phase III clinical trial of Dysport Next Generation (DNG), an injectable form of botulinum toxin type A, in cervical dystonia. DNG was clinically and statistically superior to placebo in the cervical dystonia phase III study at the dose of 500 units at week four after single dose. When compared to Dysport, DNG did not demonstrate the statistical non-inferiority in efficacy at week four. In the light of these results, Ipsen said it intends to file the ready-to-use liquid toxin A in Europe and globally.